NTRA Natera, Inc. - Common Stock

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Check out the companies making headlines yesterday:

NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.

Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceuticals and Medical Devices Agency granted regulatory approval for its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.

Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.

It wasn't just Nasdaq today. A handful of large stocks also closed at their highest levels ever. Here are some notable names with market caps above $10 billion that are sitting at all-time highs today.

Natera and its collaborators recently presented four abstracts at the IASLC 2026 World Conference on Lung Cancer, including the largest molecular residual disease dataset to date in resected stage 1–3 non-small cell lung cancer, showing that Signatera status after surgery is strongly associated with recurrence-free survival and overall survival. An important insight from these data is that Signatera-positive patients had around five times the risk of recurrence or death during surveillance,...

Natera’s updated analyst models now point to a higher Fair Value price target of US$344.33, up from US$282.14, which is roughly a 22% change in the modeled outcome. Analysts are tying this shift to how Natera is executing in molecular residual disease testing with Signatera, along with contributions from prenatal and broader oncology testing and recent regulatory and reimbursement developments. As you read on, you will see how this evolving narrative may shape how you track Natera from...

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

Natera (NTRA) demonstrates strong technical momentum, with shares hitting a new all-time high. Shares are up more than 105% over the past year. Valuation concerns persist, as Morningstar sees NTRA as 33% overvalued and multiple analysts rate it a “Hold” despite bullish technicals. I recommend holding NTRA while it trades...

With the stock market on shaky ground, investors should be adjusting their portfolio management and taking some profits. For about a half-dozen components of Investor's Business Daily's IBD 50 list, the decision on when to sell stocks is at hand. IBD's recommended market exposure is 40%-60%, so let's look at the gains that could be worth cashing in.

What a time it’s been for Natera. In the past six months alone, the company’s stock price has increased by a massive 59.9%, reaching $328.13 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Natera, Inc. (NASDAQ:NTRA) is expanding across oncology, women’s health and organ transplantation, but Jim Cramer says the stock’s valuation has become difficult to justify after a sharp rally. During the September 3 episode of Mad Money, he said, “It is an intriguing story.” He called it “a precision medicine platform,” as he advised investors to […]

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

The billionaire has good reasons to like this genetic testing leader.

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.

Natera recently announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers, expanding the use of its technology in oncology research. At the same time, Duquesne Family Office significantly increased its position in Natera, making the diagnostics company its largest healthcare holding and underscoring rising institutional interest in its MRD and medtech platform. Now we’ll explore how this...

Natera (NasdaqGS:NTRA) announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers. The Latitude assay will be used to monitor minimal residual disease and treatment response in patients receiving Kupando's investigational therapy. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumor types. This kind of cancer trial...

Duquesne Family Office has beefed up its healthcare holdings.

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

A macro trader famous for currency bets has poured more into a cancer-testing company than any other stock, and he keeps buying.

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.

The hedge fund legend has bet much of the family office on this one diagnostics company.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Natera (NASDAQ:NTRA).

NVIDIA and top institutional investors are piling into AI infrastructure, with 13F filings revealing bets on Intel, CoreWeave, Nebius and more.

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

Natera stock has delivered a very large 3 year gain, yet its valuation checks send mixed signals, with a Discounted Cash Flow (DCF) estimate suggesting the share price sits well below intrinsic value while market multiples point to an expensive stock. The share price has risen by roughly 4.9x over 3 years, which puts a lot of past optimism into the current valuation. Recent progress in expanding the use of its tests in oncology and related clinical settings can support long term growth...

Natera (NTRA) has drawn fresh attention after announcing a new collaboration that puts its Latitude molecular residual disease test into a Phase 1 clinical trial for Kupando Therapeutics’ lead immunotherapy candidate, KUP-101. See our latest analysis for Natera. The latest collaboration news comes after an active stretch for Natera, with recent earnings, raised 2026 revenue guidance and regulatory milestones in Japan helping underpin strong momentum. The stock’s share price return of 60.97%...

Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrow

Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and emerging product lines. Management attributed the quarter’s strength to record-breaking test volumes—particularly for Signatera in oncology—and the successful launch of an enhanced Panorama prenatal test. CEO Steven Chapman highlighted increased adoption across tumor types and cited critical milestones, including FDA and Japanese regulatory app

Oncology volumes jumped 57.2% on MRD adoption gains.

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $752.8 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 3% above analysts’ estimates. Its non-GAAP loss of $0.47 per share was 12% above analysts’ consensus estimates.

Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.

This sale was executed under a pre-arranged Rule 10b5-1 trading plan.

This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.

This was a non-discretionary sale to cover tax withholding on vesting equity awards under a Rule 10b5-1 plan.

Sheena executed 9,150 shares under a pre-established trading plan adopted in December 2025.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

In early August 2026, Natera filed an US$849.22 million shelf registration for 3,200,000 common shares tied to its employee stock plans, shortly after reporting record quarterly test volumes and raising full-year 2026 revenue guidance to US$2.85 billion–US$2.91 billion. The company’s push to expand regulatory approvals for its Signatera molecular residual disease test, including a new companion diagnostic application in Japan for muscle-invasive bladder cancer, underpins its efforts to...

Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.

SpaceX's gravitational pull is undeniable. That's why it's unsurprising that a few offhand remarks in SpaceX's earnings call on Tuesday still managed to jolt stocks in the further reaches of the company's orbit.

Natera stock surged Friday after reporting blowout volume for its cancer-detecting blood test, Signatera, in the second quarter.

Moby summary of Natera, Inc.'s Q2 2026 earnings call